Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial.

Kaveh Kazemian, Shahram Ala, Mojtaba Mojtahedzadeh, Mahmoud Abedini, Abbas Alipour, Saeid Abediankenari, Mohammadreza Rafati, Ali Abaskhanidavanloo, Fatemeh Mohajerani
{"title":"Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial.","authors":"Kaveh Kazemian,&nbsp;Shahram Ala,&nbsp;Mojtaba Mojtahedzadeh,&nbsp;Mahmoud Abedini,&nbsp;Abbas Alipour,&nbsp;Saeid Abediankenari,&nbsp;Mohammadreza Rafati,&nbsp;Ali Abaskhanidavanloo,&nbsp;Fatemeh Mohajerani","doi":"10.22037/ijpr.2020.1100952","DOIUrl":null,"url":null,"abstract":"<p><p>Cerebral infarction presents with neurological deficits caused by the death of neurons in a focal area of the brain. S100B is a biomarker that increases in brain damage. Neuroprotectives can reduce the brain sequels after neurological insult. The purpose of this study was to evaluate the neuroprotective effects of L-carnitine and Fat emulsion (Lipofundin<sup>®</sup>) alone and in combination in patients with ischemic stroke. In a prospective, RCT, and double-blind study 100 patients with MCA ischemic cerebrovascular accident who were admitted in the first 24 h of injury entered the study. The patients were randomly assigned into four groups of L-carnitine, fat emulsion, L-carnitine plus fat emulsion and control. Fat emulsion 10%, 500 mL, was infused over 6 to 12 h and 1 gr of L-carnitine (10 mL of solution) was administered orally to patients in addition to common therapies, according to the American Heart Association and American Stroke Association (AHA/ASA) guidelines. The patients in the control group received only the usual treatment according to stroke guidelines. Blood samples before the intervention, then after 24 h, 48 h, and 7 days later were taken and immunoenzymatic colorimetric method was used for quantitative determination of S100B concentration in the patients' serum. In the within group analysis, all of our treatment interventions (except control group) have decreased S100B levels statistically significant (<i>P</i> < 0.05). Moreover, changes in observed levels of S100B before and after intervention were different between the groups and the observed differences were statistically significant (<i>P</i> = 0.01). In the GEE model, it was found that S100B levels in the L-carnitine plus fat emulsion group decreased more than the control group and this decline has been statistically significant [<i>P</i> = 0.02, 20.47 (CI 95%: 6.25-34.41)], but in comparison of L-carnitine and fat emulsion group with control group, did not reached statistical significance (<i>P</i> > 0.05). Based on the results obtained from this study, it seems that L-carnitine with fat emulsion could lead to neuroprotective effects with a significant reduction in the S100B biomarker.</p>","PeriodicalId":416671,"journal":{"name":"Iranian Journal of Pharmaceutical Research : IJPR","volume":" ","pages":"111-119"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462480/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pharmaceutical Research : IJPR","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.22037/ijpr.2020.1100952","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Cerebral infarction presents with neurological deficits caused by the death of neurons in a focal area of the brain. S100B is a biomarker that increases in brain damage. Neuroprotectives can reduce the brain sequels after neurological insult. The purpose of this study was to evaluate the neuroprotective effects of L-carnitine and Fat emulsion (Lipofundin®) alone and in combination in patients with ischemic stroke. In a prospective, RCT, and double-blind study 100 patients with MCA ischemic cerebrovascular accident who were admitted in the first 24 h of injury entered the study. The patients were randomly assigned into four groups of L-carnitine, fat emulsion, L-carnitine plus fat emulsion and control. Fat emulsion 10%, 500 mL, was infused over 6 to 12 h and 1 gr of L-carnitine (10 mL of solution) was administered orally to patients in addition to common therapies, according to the American Heart Association and American Stroke Association (AHA/ASA) guidelines. The patients in the control group received only the usual treatment according to stroke guidelines. Blood samples before the intervention, then after 24 h, 48 h, and 7 days later were taken and immunoenzymatic colorimetric method was used for quantitative determination of S100B concentration in the patients' serum. In the within group analysis, all of our treatment interventions (except control group) have decreased S100B levels statistically significant (P < 0.05). Moreover, changes in observed levels of S100B before and after intervention were different between the groups and the observed differences were statistically significant (P = 0.01). In the GEE model, it was found that S100B levels in the L-carnitine plus fat emulsion group decreased more than the control group and this decline has been statistically significant [P = 0.02, 20.47 (CI 95%: 6.25-34.41)], but in comparison of L-carnitine and fat emulsion group with control group, did not reached statistical significance (P > 0.05). Based on the results obtained from this study, it seems that L-carnitine with fat emulsion could lead to neuroprotective effects with a significant reduction in the S100B biomarker.

Abstract Image

Abstract Image

左旋肉碱和脂肪乳剂对CVA患者神经保护作用的评价:一项前瞻性、随机、双盲临床试验。
脑梗塞表现为神经功能缺损,是由大脑局部区域的神经元死亡引起的。S100B是一种增加脑损伤的生物标志物。神经保护剂可以减少神经损伤后的脑后遗症。本研究的目的是评估左旋肉碱和脂肪乳剂(Lipofundin®)单独和联合使用对缺血性脑卒中患者的神经保护作用。在一项前瞻性、随机对照试验和双盲研究中,100例MCA缺血性脑血管意外患者在受伤后24小时内入院。将患者随机分为左旋肉碱组、脂肪乳组、左旋肉碱加脂肪乳组和对照组。根据美国心脏协会和美国中风协会(AHA/ASA)指南,10%的脂肪乳剂,500毫升,输注6至12小时,除常规治疗外,患者口服1克左旋肉碱(10毫升溶液)。对照组患者仅按照卒中指南接受常规治疗。分别于干预前、干预后24 h、48 h、7 d采血,采用免疫酶比色法定量测定患者血清中S100B浓度。在组内分析中,除对照组外,我们的所有治疗干预措施均降低了S100B水平,具有统计学意义(P < 0.05)。干预前后组间S100B观察值变化差异有统计学意义(P = 0.01)。在GEE模型中,我们发现左旋肉碱加脂肪乳组S100B水平下降幅度大于对照组,且下降幅度有统计学意义[P = 0.02, 20.47 (CI 95%: 6.25-34.41)],但左旋肉碱加脂肪乳组与对照组比较,S100B水平未达到统计学意义(P > 0.05)。根据本研究的结果,左卡尼汀与脂肪乳可能通过显著降低S100B生物标志物而导致神经保护作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书